Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Oct 2;12(10):901. doi: 10.1038/s41419-021-04155-z

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2021

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 4 — A The scheme of process of choosing patients; B Representative images of high and low expression of PLEK2 (left) and Kaplan-Meier plots of OS of patients who received chemotherapy in the database GSE53625 (right); C The apoptosis rate of PLEK2 stably knockdown KYSE-30 cells; D Western blot analysis of markers of cell apoptosis including Bax, Cleaved PARP, Caspase 3 and Caspase 9. Tubulin was used as loading control; E The apoptosis rate of PLEK2 stably knockdown KYSE-30 cells after the treatment of DDP for 24 h; F Western blot analysis of markers of cell apoptosis; G The apoptosis rate of KYSE-30 with PLEK2 stably overexpressed after the treatment of DDP for 24 h; H Representative images of IHC in KYSE-30 xenograft tumours treated with varying dosage of DDP.